Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 18/20 | 1.00 |
| ▸ | ACP1 | P24666 | 1/20 | 0.65 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17287791 | 0.89 | CSNK1D (1.00) | CSNK1DACP1DYRK1A | |
| SCHEMBL17287767 | 0.89 | CSNK1D (1.00) | CSNK1DACP1DYRK1A | |
| SCHEMBL17287559 | 0.88 | CSNK1D (1.00) | CSNK1DACP1DYRK1A | |
| SCHEMBL17287839 | 0.86 | CSNK1D (1.00) | CSNK1D | |
| SCHEMBL17287650 | 0.85 | CSNK1D (1.00) | CSNK1DACP1DYRK1A | |
| SCHEMBL18851067 | 0.83 | CSNK1D (0.71) | CSNK1DDYRK1A | |
| SCHEMBL17287680 | 0.83 | CSNK1D (1.00) | CSNK1DACP1DYRK1A | |
| SCHEMBL30522065 | 0.81 | CSNK1D (0.74) | CSNK1DACP1DYRK1A | |
| SCHEMBL29095959 | 0.81 | CSNK1D (0.74) | CSNK1DACP1DYRK1A | |
| SCHEMBL17287812 | 0.80 | CSNK1D (1.00) | CSNK1DACP1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3348550-B1 | SUBSTITUTED BENZOTHIAZOLES AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF HUMAN DISEASES | CONSEJO SUPERIOR INVESTIGACION (ES) | 2019-04-24 | — | — | EP | claimed |
| EP-3348550-A1 | SUBSTITUTED BENZOTHIAZOLES AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF HUMAN DISEASES | Consejo Superior de Investigaciones Cientificas (CSIC) (ES) | 2018-07-18 | — | — | EP | claimed |
| US-9592224-B2 | Substituted benzothiazoles and therapeutic uses thereof for the treatment of human diseases | DONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (ES) | 2017-03-14 | — | — | US | claimed |
| US-20150352082-A1 | SUBSTITUTED BENZOTHIAZOLES AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF HUMAN DISEASES | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) | 2015-12-10 | — | — | US | claimed |
| EP-2949651-A1 | SUBSTITUTED BENZOTHIAZOLES AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF HUMAN DISEASES | Consejo Superior De Investigaciones Científicas (CSIC) (ES) | 2015-12-02 | — | — | EP | claimed |
| EP-3348550-B1 | SUBSTITUTED BENZOTHIAZOLES AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF HUMAN DISEASES | CONSEJO SUPERIOR INVESTIGACION (ES) | 2019-04-24 | — | — | EP | disclosed |
| EP-3348550-A1 | SUBSTITUTED BENZOTHIAZOLES AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF HUMAN DISEASES | Consejo Superior de Investigaciones Cientificas (CSIC) (ES) | 2018-07-18 | — | — | EP | disclosed |
| US-9592224-B2 | Substituted benzothiazoles and therapeutic uses thereof for the treatment of human diseases | DONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (ES) | 2017-03-14 | — | — | US | disclosed |
| US-20150352082-A1 | SUBSTITUTED BENZOTHIAZOLES AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF HUMAN DISEASES | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) | 2015-12-10 | — | — | US | disclosed |
| EP-2949651-A1 | SUBSTITUTED BENZOTHIAZOLES AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF HUMAN DISEASES | Consejo Superior De Investigaciones Científicas (CSIC) (ES) | 2015-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150352082-A1 | SUBSTITUTED BENZOTHIAZOLES AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF HUMAN DISEASES | CSNK1A1, CRY1, CSNK1G1 | CSNK1D 13/4885ACP1 697/4885DYRK1A 1050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.